A 48-year-old woman on lithium carbonate 900 mg daily for bipolar I disorder presents with polyuria (3 L/day), polydipsia, and a serum lithium level of 0.8 mEq/L (therapeutic). Which finding best distinguishes nephrogenic diabetes insipidus secondary to lithium from central diabetes insipidus?

Explanation

## Nephrogenic DI vs Central DI in Lithium Toxicity ### Pathophysiology **Key Point:** Lithium causes nephrogenic diabetes insipidus (NDI) by blocking aquaporin-2 water channel expression in the collecting duct, rendering the kidney unresponsive to antidiuretic hormone (ADH/vasopressin). This is fundamentally different from central DI, where ADH production is deficient. ### Diagnostic Distinction: DDAVP Challenge Test | Feature | Nephrogenic DI (Lithium) | Central DI | |---------|---|---| | **Baseline urine osmolality** | Low (<300 mOsm/kg) | Low (<300 mOsm/kg) | | **After DDAVP challenge** | No significant increase (<50 mOsm/kg rise) | Increases to >600 mOsm/kg | | **Serum ADH level** | Normal or elevated | Low | | **Mechanism** | Kidney unresponsive to ADH | Insufficient ADH production | | **Reversibility** | Partially reversible; improves with amiloride or NSAIDs | Fully reversible with DDAVP replacement | | **Serum osmolality** | Elevated (>295 mOsm/kg) | Elevated (>295 mOsm/kg) | ### High-Yield Discriminator **High-Yield:** The DDAVP stimulation test is the gold standard. In nephrogenic DI (lithium-induced), urine osmolality remains low (<300 mOsm/kg) or increases minimally despite DDAVP administration because the collecting duct is refractory to ADH. In central DI, urine osmolality rises briskly to >600 mOsm/kg because the kidneys are responsive to exogenous DDAVP. ### Clinical Pearl **Clinical Pearl:** A patient on lithium presenting with polyuria and polydipsia who fails to concentrate urine after DDAVP challenge has nephrogenic DI. This is a known dose-dependent and partially reversible adverse effect of lithium. Amiloride (a potassium-sparing diuretic) can reduce polyuria by blocking lithium entry into collecting duct cells. ### Mechanism of Lithium-Induced NDI Lithium inhibits inositol monophosphatase, depleting intracellular inositol and disrupting the phosphatidylinositol signaling pathway. This leads to downregulation of aquaporin-2 (AQP2) water channels in the collecting duct principal cells, preventing water reabsorption even in the presence of ADH. [cite:Harrison's Principles of Internal Medicine 21e Ch 297]